This combination aims to help people get the maximum benefits of semaglutide while reducing the uncomfortable GI side effects associated with GLP-1 medications
Approved: 05/2026 Instructions for Use - FlexTouch INSTRUCTIONS FOR USE SECTION INSTRUCTIONS FOR USE WEGOVY (wee-GOH-vee) FlexTouch (semaglutide) injection, for subcutaneous use 2.4 mg dose single-patient-use pen Each pen contains 4 fixed doses, one dose taken weekly Unfold the whole leaflet and read these instructions carefully before using your WEGOVY FlexTouch single-patient-use pen
Noapproximately 20 percent of semaglutide patients experience minimal nausea or skip it entirely, while others feel it within 24 to 72 hours
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services
Participants receiving semaglutide 2.4 mg weekly achieved mean weight loss of 35 pounds, while those on placebo lost 6 pounds
Semaglutide relies on higher single-pathway activation, pushing GLP-1 receptor stimulation further